Transitioning from an originator agent to its biosimilar has the potential to reduce healthcare costs without compromising outcomes.
The use of tumor necrosis factor inhibitors to modify structural changes in axial spondyloarthritis may prevent progression to spinal disease.
For patients with ankylosing spondylitis, secukinumab may reduce radiographic progression and remain effective in the long-term.
Tofacitinib may provide an alternate therapeutic mechanism of action for patients with psoriatic arthritis who have failed prior treatment with conventional synthetic disease-modifying antirheumatic drugs.
Researchers found that HLA status was associated with gut microbiota diversity.
The guideline includes recommendations for treating adult patients with active psoriatic arthritis.
Treatment with TNF inhibitors has led to improvement in physical function and quality of life in patients with ankylosing spondylitis.
Results from phase 3 trials OPAL Broaden (NCT01877668) and OPAL Beyond (NCT01882439) presented at the American College of Rheumatology 2017 in San Diego, California.
Researchers recruited patients with recent onset axial spondyloarthritis and conducted MRI of the spine or MRI of the sacroiliac joints at baseline, 2 years, and 5 years.
Researchers observed a higher prevalence of psychiatric disorders among female patients with psoriatic arthritis.
Regardless of dose, patients taking secukinumab were more likely to experience no radiographic progression compared with placebo.
Real-world data indicate that although most patients with systemic lupus erythematosus or connective tissue diseases have successful pregnancies, more adverse pregnancy outcomes occur.
Investigators sought to determine the long-term safety of adalimumab use in patients with arthritis and other immune-related diseases.
Inhibitors of interkeukins 6, 12, 23 and 17A were shown to be effective and generally well-tolerated agents for the treatment of psoriatic arthritis.
Study confirms the validity of previously identified bone-turnover biomarkers for psoriatic disease-associated arthritis and for axial arthritis.
In patients with recent-onset axial spondyloarthritis (axSpA), the long-term use of etanercept may result in a lower rate of radiographic progression in the sacroiliac joint.
TNFi therapy in ankylosing spondylitis has a clinically relevant inhibitory effect on spinal radiographic progression.
Results from the FUTURE 2 study show that secukinumab improves signs and symptoms in patients with active psoriatic arthritis through 2 years of therapy.
Predictors of subclinical accelerated atherosclerosis were examined in a recent study of patients with spondyloarthritis without overt cardiovascular disease.
HBV reactivation rates were lower among all chronic HBV infection patients on antiviral prophylaxis, regardless of whether they were receiving TNF inhibitors.
The first lactation study of its kind evaluated whether a biologic drug is transferred into mature breast milk
Researchers recommended against including MRI in the Assessment of Spondyloarthritis International Society classification criteria for axial spondyloarthritis.
To improve pain relief, surgeons should proactively address stress, distress, and ineffective coping strategies.
A study analyzes whether underlying sacroiliac erosions may be present in patients with nonradiographic axial spondylarthritis who have normal radiographs.
The ability of Power Doppler Ultrasound to predict short-term psoriatic arthritis disease flare was investigated in a new study.
The researchers noted that the small changes in lipid profile do not account for the cardiovascular benefits seen in patients taking etanercept.
Serum leptin and high molecular weight adiponectin have an inverse relationship with radiographic spinal progression in patients with ankylosing spondylitis.
Determining which patients are unlikely to respond to therapy early on may help reduce unnecessary treatment and contain costs.
Repeated serum amyloid A measurements could act as an additional marker for monitoring disease activity over time in patients with psoriatic arthritis.
Ixekizumab was found to benefit patients with psoriatic arthritis showing poor response to conventional treatment when administered over a 2- or 4-week period.
Rheumatology Advisor Articles
- Promising Antibody Markers Identified for aPL-Related Pregnancy Complications
- Comorbid Fibromyalgia Influences Disease Activity, Quality of Life in Axial Spondyloarthritis
- Efficacy of ABT-122 Maintained in Psoriatic Arthritis, Rheumatoid Arthritis at 36 Weeks
- Knee Load Associated With Increased Walking Pain in Osteoarthritis
- Pain Catastrophizing Decreases in Rheumatoid Arthritis After DMARD Initiation
- Genetic Screening May Predict Osteoporosis, Fracture Risk
- Exploring the Clinical Implications of Cannabinoid Use in Rheumatoid Arthritis
- Diagnosing Lyme Disease in Children With Neuropsychiatric Illness
- Predicting Primary Nonresponse to Methotrexate in Rheumatoid Arthritis
- Prednisone, Prednisolone Does Not Adversely Affect Bone Mineral Density in RA
- Characteristics of Early-Onset SLE Distinguished From Mimicking Conditions
- Uric Acid Predicts AKI Risk After Cardiac Surgery
- Examining Gaps in Mental Health Care Among Youth With Juvenile Rheumatic Disease
- AMA Proposes Policy Opposing Medicaid 'Lockout' Provisions
- TNFi Not Linked to Increased Risk for Cancer Recurrence in Rheumatoid Arthritis